Stay updated with breaking news from Giordano bott. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ -- The UAB Cardiogenomics Clinic, led by Dr. Pankaj Arora, is partnering with the industry leader for polygenic risk score (PRS) analysis and...
/PRNewswire/ -- Allelica, a leading genomics software company that provides digital tools for the development, validation and calculation of ancestry-specific...
/PRNewswire/ -- Allelica, a leading genomic software company specializing in secure and scalable solutions to implement clinical-grade PRS, has published a...
/PRNewswire/ -- Allelica, a leading genomics software company that develops digital tools to develop, validate and calculate PRS for common diseases, announced...
/PRNewswire/ -- Allelica, a leading genomics software company that develops digital tools to develop, validate and calculate PRS for common diseases, announced...
(1) PRS stratifies disease risk and brings precision medicine into clinical routine Allelica, a leading genomics software company specialising in developing polygenic risk scores (PRSs) for common diseases, today announced that the company has raised $1.75 million in a seed financing round led by Valor Ventures, Sternberg Health, Pi Campus, as well as strategic business angels also participated in the round. As part of the transaction, Valor Ventures General Partner Gary Peat has joined the Allelica board of directors and Allelica has relocated its headquarters to New York City. The proceeds of the financing will be used to advance clinical integration of Allelica's PRS software into healthcare systems in the US. A PRS is a measurement of a person's risk of disease based on their genes and is based on combining the effects of a large number of genetic variants across the genome. This information can be used to stratify individuals based on their risk of disease. By combining PRS with conventional risk factors, Allelica believes precision medicine at scale can be achieved. Allelica has built digital tools for estimating an individual's PRS for multiple diseases, including coronary artery disease (CAD), breast cancer, prostate cancer, colon cancer, Type 2 diabetes and Alzheimer's disease. Demonstrating the importance of PRS, in a recent publication in Circulation, Allelica's PRS for CAD showed that the levels of LDL cholesterol do not affect a person's risk of heart attack in the same way. Millions of people with average LDL could be in danger of a heart attack because they also have a high PRS and should probably take lipid lowering medications. Conversely, there are people who are taking these drugs but potentially may not need to because their genes protect them.
Allelica's polygenic risk score data published in Circulation Halsin Partners E-Mail Rome, Italy, March 8, 2021 - Allelica, a leading genomics software company specialising in developing polygenic risk scores (PRS) for personalised medicine, today announced publication of a study in Circulation (Vol. 143, Issue 10) showing that the effect of LDL cholesterol on a person's risk of having a heart attack depends on their genes. Using Allelica's proprietary PRS analysis software, the data showed that combining information on an individual's genetic risk of heart attack with their LDL level helps determine those at most risk from heart attack, including those potentially in need of treatment with statins or PCSK9 inhibitors. The PRS was also able to identify individuals eligible for therapeutic intervention based on current guidelines, which do not include polygenic risk, but who are in fact at low risk of heart attack based on their genes and LDL levels, so could potentially avoid treatment. A PRS is a measurement of a person's risk of disease based on their genes and is based on combining the effects of a large number of genetic variants across the genome.
Allelica's polygenic risk score data published in Circulation sciencecodex.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from sciencecodex.com Daily Mail and Mail on Sunday newspapers.